Colgate Palmolive India Appoints Manish Anandani as New MD & CEO
Colgate-Palmolive India's Board accepted MD & CEO Prabha Narasimhan's resignation, effective September 27, 2026. Manish Anandani appointed as new MD & CEO for five years from September 28, 2026. Anandani brings 30 years of experience and previously worked with the company.
A change in the Managing Director and CEO position is a significant event for a company, impacting its strategic direction and operations.
The announcement details a leadership change, which is a routine corporate event. While the new appointment is positive for the company's future leadership, the departure of a key executive is neutral.
Colgate-Palmolive (India) Limited announced a change in its leadership following a Board of Directors meeting held on August 21, 2026. The Board accepted the resignation of Ms. Prabha Narasimhan as the Managing Director and Chief Executive Officer, effective September 27, 2026. Ms. Narasimhan will be taking on a new role as Executive Vice President - Marketing, Asia-Pacific Division of Colgate-Palmolive.
Concurrently, the Board approved the appointment of Mr. Manish Anandani as the new Managing Director and Chief Executive Officer for a term of five years, commencing September 28, 2026. This appointment is subject to shareholder and other necessary statutory approvals. Mr. Anandani brings over 30 years of experience in sales, marketing, general management, and senior leadership roles, having previously served as Managing Director for India and South Asia at Kenvue (erstwhile Johnson & Johnson Consumer Health). He also has prior experience with Colgate-Palmolive, having worked there from 2005 to 2018 in various capacities.
The Board meeting commenced at 8:00 a.m. IST and concluded at 8:45 a.m. IST on August 21, 2026.
What to do with a filing like this
Colgate Palmolive (India) Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Colgate Palmolive (India) Limited. Read the original for the full detail.